Sandeep K Goyal1, Li Wang2, Raghu Upender3, Dawood Darbar4, Ken Monahan1. 1. Division of Cardiovascular Medicine. 2. Department of Biostatistics. 3. Division of Sleep Medicine/Department of Neurology. 4. Division of Cardiovascular Medicine ; Division of Clinical Pharmacology, Vanderbilt Medical Center, Nashville, TN.
Abstract
STUDY OBJECTIVES: To examine the impact of genotype on the relationship between obstructive sleep apnea (OSA) and anti-arrhythmic drug (AAD) efficacy in atrial fibrillation (AF). DESIGN: Registry based. SETTING: Clinic-based. PARTICIPANTS: Eighty-four individuals from Vanderbilt AF registry who had polysomnography, genotyping, and serial comprehensive evaluations of AF status. INTERVENTIONS: None. MEASUREMENTS AND RESULTS: Response to AADs was defined as a decrease in AF burden score by ≥ 75% or the combination of sinus rhythm on follow-up EKGs, stable AAD therapy for at least 6 months, objective AF burden below an established threshold, and the absence of non-pharmacologic therapies. Participants were genotyped for common AF susceptibility alleles at chromosomes 4q25 (near PITX2), 16q22 (in ZFHX3), and 1q21 (in KCNN3), and common SNPs in the β1-adrenergic receptor (ARDB1). Wild-type status for rs10033464 at 4q25 was associated with increased success of AAD therapy in patients with no or mild OSA (odds ratio: 10.0, 95% confidence interval: 1.03 to 97.5; p < 0.05), but did not influence response to AAD therapy in those with moderate-severe OSA. A similar trend was observed for rs1801252 on ARDB1. CONCLUSION: In this hypothesis-generating pilot study of predominantly Caucasian men, the effect on AF response to AAD therapy of rs10033464 at 4q25 varied based on OSA status. The impact of genotype on AAD efficacy may be greatest in mild OSA and attenuated in more severe disease.
STUDY OBJECTIVES: To examine the impact of genotype on the relationship between obstructive sleep apnea (OSA) and anti-arrhythmic drug (AAD) efficacy in atrial fibrillation (AF). DESIGN: Registry based. SETTING: Clinic-based. PARTICIPANTS: Eighty-four individuals from Vanderbilt AF registry who had polysomnography, genotyping, and serial comprehensive evaluations of AF status. INTERVENTIONS: None. MEASUREMENTS AND RESULTS: Response to AADs was defined as a decrease in AF burden score by ≥ 75% or the combination of sinus rhythm on follow-up EKGs, stable AAD therapy for at least 6 months, objective AF burden below an established threshold, and the absence of non-pharmacologic therapies. Participants were genotyped for common AF susceptibility alleles at chromosomes 4q25 (near PITX2), 16q22 (in ZFHX3), and 1q21 (in KCNN3), and common SNPs in the β1-adrenergic receptor (ARDB1). Wild-type status for rs10033464 at 4q25 was associated with increased success of AAD therapy in patients with no or mild OSA (odds ratio: 10.0, 95% confidence interval: 1.03 to 97.5; p < 0.05), but did not influence response to AAD therapy in those with moderate-severe OSA. A similar trend was observed for rs1801252 on ARDB1. CONCLUSION: In this hypothesis-generating pilot study of predominantly Caucasian men, the effect on AF response to AAD therapy of rs10033464 at 4q25 varied based on OSA status. The impact of genotype on AAD efficacy may be greatest in mild OSA and attenuated in more severe disease.
Authors: Jan Börgel; Tino Schulz; Nina K Bartels; Jörg T Epplen; Nikolaus Büchner; Lars Christian Rump; Anika Huesing; Bernd M Sanner; Andreas Mügge Journal: Clin Sci (Lond) Date: 2006-01 Impact factor: 6.124
Authors: Chee Yuan Ng; Tong Liu; Michael Shehata; Steven Stevens; Sumeet S Chugh; Xunzhang Wang Journal: Am J Cardiol Date: 2011-04-29 Impact factor: 2.778
Authors: Emelia J Benjamin; Peng-Sheng Chen; Diane E Bild; Alice M Mascette; Christine M Albert; Alvaro Alonso; Hugh Calkins; Stuart J Connolly; Anne B Curtis; Dawood Darbar; Patrick T Ellinor; Alan S Go; Nora F Goldschlager; Susan R Heckbert; José Jalife; Charles R Kerr; Daniel Levy; Donald M Lloyd-Jones; Barry M Massie; Stanley Nattel; Jeffrey E Olgin; Douglas L Packer; Sunny S Po; Teresa S M Tsang; David R Van Wagoner; Albert L Waldo; D George Wyse Journal: Circulation Date: 2009-02-03 Impact factor: 29.690
Authors: Patrick T Ellinor; Kathryn L Lunetta; Nicole L Glazer; Arne Pfeufer; Alvaro Alonso; Mina K Chung; Moritz F Sinner; Paul I W de Bakker; Martina Mueller; Steven A Lubitz; Ervin Fox; Dawood Darbar; Nicholas L Smith; Jonathan D Smith; Renate B Schnabel; Elsayed Z Soliman; Kenneth M Rice; David R Van Wagoner; Britt-M Beckmann; Charlotte van Noord; Ke Wang; Georg B Ehret; Jerome I Rotter; Stanley L Hazen; Gerhard Steinbeck; Albert V Smith; Lenore J Launer; Tamara B Harris; Seiko Makino; Mari Nelis; David J Milan; Siegfried Perz; Tõnu Esko; Anna Köttgen; Susanne Moebus; Christopher Newton-Cheh; Man Li; Stefan Möhlenkamp; Thomas J Wang; W H Linda Kao; Ramachandran S Vasan; Markus M Nöthen; Calum A MacRae; Bruno H Ch Stricker; Albert Hofman; André G Uitterlinden; Daniel Levy; Eric Boerwinkle; Andres Metspalu; Eric J Topol; Aravinda Chakravarti; Vilmundur Gudnason; Bruce M Psaty; Dan M Roden; Thomas Meitinger; H-Erich Wichmann; Jacqueline C M Witteman; John Barnard; Dan E Arking; Emelia J Benjamin; Susan R Heckbert; Stefan Kääb Journal: Nat Genet Date: 2010-02-21 Impact factor: 38.330
Authors: Ken Monahan; Amy Storfer-Isser; Reena Mehra; Eyal Shahar; Murray Mittleman; Jeff Rottman; Naresh Punjabi; Mark Sanders; Stuart F Quan; Helaine Resnick; Susan Redline Journal: J Am Coll Cardiol Date: 2009-11-03 Impact factor: 24.094
Authors: Ravi Kanagala; Narayana S Murali; Paul A Friedman; Naser M Ammash; Bernard J Gersh; Karla V Ballman; Abu S M Shamsuzzaman; Virend K Somers Journal: Circulation Date: 2003-05-12 Impact factor: 29.690
Authors: Neel J Patel; Quinn S Wells; Shi Huang; Raghu P Upender; Dawood Darbar; Ken Monahan Journal: Am J Cardiol Date: 2017-02-10 Impact factor: 2.778
Authors: Karan R Chadda; Ibrahim T Fazmin; Shiraz Ahmad; Haseeb Valli; Charlotte E Edling; Christopher L-H Huang; Kamalan Jeevaratnam Journal: Sleep Date: 2018-09-01 Impact factor: 5.849
Authors: Giuseppe Boriani; Irina Savelieva; Gheorghe-Andrei Dan; Jean Claude Deharo; Charles Ferro; Carsten W Israel; Deirdre A Lane; Gaetano La Manna; Joseph Morton; Angel Moya Mitjans; Marc A Vos; Mintu P Turakhia; Gregory Y H Lip Journal: Europace Date: 2015-06-24 Impact factor: 5.214
Authors: Shinwan Kany; Bruno Reissmann; Andreas Metzner; Paulus Kirchhof; Dawood Darbar; Renate B Schnabel Journal: Cardiovasc Res Date: 2021-06-16 Impact factor: 10.787
Authors: Jordi Heijman; Henry Sutanto; Harry J G M Crijns; Stanley Nattel; Natalia A Trayanova Journal: Cardiovasc Res Date: 2021-06-16 Impact factor: 10.787